Participating in the trial. We want to break it down more. What do we know . What are the questions . Reporter pfizer is telling us they have a vaccine that appears to be more than 90 effective. They studied this immunization in 43,000 people, and within about a week after the second dose, they found that more than 90 of people who got the vaccine were protected against the actual coronavirus. Know that it didnt take very long. We dont know the actual numbers of how we people were infected, but if we are looking at more than a 90 effectiveness rate, which was much higher than anyone expected, we are getting suggestions that this vaccine is quickly protective for many people. We still dont have news on how long it is going to last. We dont know whether or not there will be any safety signals. After that, they might be filing for emergency use authorization. Jonathan what kind of vaccine is this alix what kind of vaccine is this . Vaccine. It is an mrna theres nothing like this that exis
Cheaper auction it could be a cheaper option. Tom we will talk about that with sam fazeli. Over here it is about the hospitalization. It has been an extraordinarily difficult pandemic weekend fulltime america tries to move on, and someone moving on is the president elect with news from bloomberg overnight on appointments to be had, i believe, tuesday. Even while the president contests in wisconsin. Francine we will have a full round up of u. S. Elections as well. Lets get to bloomberg first word news with ritika gupta. Ritika another Promising Development in the fight to end the coronavirus pandemic. The vaccine developed by the university of oxford as astrazeneca prevented a majority of people in a large trial from getting the disease. It stop and average from 70 from falling ill, below the high bar set by pfizer and moderna, but effectiveness did rise to 90 for one of two dosing regimes. Joe biden plans to name anthony en as secretary of state. When he was when biden was Vice Preside
Testimony from the dhs regarding its decision to ban residents of new york state from trusted Traveler Programs like global entry. Like global entry. On february 5, senior ghs official chad wolfe wrote to new york officials to inform them of the ban, without notifying congress and the members of the new york state delegation who sit on this authorizing committee. Mr. Wolf cited new yorks green light law, a justification for the ban, stating that the law, quote, compromises cbps ability to confirm whether an individual applying for ttp membership meets Program Eligibility requirements. Mr. Wolf then stated, quote, because the act prevents dhs from accessing new york dmv records in order to determine whether a ttp applicant or reapplicant meets Program Eligibility requirements, new York Resident wills no longer be eligible to enroll or reenroll in cbps trusted Traveler Programs. After that announcement, this committee continued to receive inaccurate and misleading testimony that repeated
This is boom bust the one business show you cant afford to miss ive been sworn in washington coming up at woodys and big point continue to rally another huge day for the stock market all of this despite the idea that remember stocks were supposed to drop on a contentious general election and were going to talk about the Federal Reserve today why your own power may be laying low for the moment how long will that last we got a lot to get to so lets get started. And we begin today with the latest on the coronavirus as cases have exceeded 100000 new cases reported in a single day its the 1st time that has happened the number of new coated cases appears to be soaring across the midwest and the plains states in fact new reports show that 7 states have now set records for hospitalizations for covert 19 the states of connecticut maine michigan minnesota nebraska and north dakota jumps of more than 45 percent and their 7 day rolling average new data also shows us that the data that 1907 deaths
With its trial. There were two trial participants. One had efficacy of 90 . The other was lower than that, in the 60s. You average that, and it its about 70 . We will see how the market is moving on that. We want to welcome now to our bloomberg tv and radio on a sense Radio Audience astrazenecas executive vice president. It is really good to see you. When itways welcome, comes to good news over solid vaccines. The question it seems people want insert is talk about that 90 efficacy. That seems to have been a smaller group. Give me some insight into it. How many confirmed cases were there in that group . Try tot of all, let me summarize the headline data. Overall, we have seen efficacy about two efficacy of up to 90 and about half of those in the Clinical Trial. We have seen roughly 3000 volunteers in that cohort of the Clinical Trial, and it was highly significant that we saw less infections, and in fact, across all of the cohorts, you other the cohorts, whether you had the full dose, t